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Abstract: Recent advances in the understanding of the pathophysiology of ulcerative colitis
(UC) have led to the expansion of our therapeutic arsenal. Conventional treatment options,
including aminosalicylates, corticosteroids, thiopurines, and calcineurin inhibitors, fail to
control the disease in a signiﬁcant proportion of patients. Approximately 25–50% of the
patients treated with tumor necrosis factor antibodies (anti-TNFα) are primary and secondary
non-responders to therapy. Tofacitinib is a novel orally administered small synthetic mole-
cule that inhibits a homologous family of enzymes, termed Janus kinases that modulate
multiple key cytokines involved in the pathogenesis of UC. Phase II and III trials showed
promising results in UC, leading the Food and Drug Administration (FDA) and the European
Medicines Agency (EMA) to approve its administration for the induction and maintenance of
remission in moderate-to-severe UC. Herein, we review tofacitinib for the management of
UC, its mechanism of action pharmacokinetic properties, efﬁcacy, and safety.
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Introduction
Ulcerative colitis (UC) is an idiopathic immune-mediated inﬂammatory bowel
disease of the colon.1 It is often diagnosed in the third and fourth decades of life2
and leads to signiﬁcant mortality and morbidity.3 Both UC and Crohn’s disease are
associated with economic impact from hospitalization and surgery and also loss of
productivity at work.3,4
More than 80% of the UC patients run a relapsing disease course, whereas 10–15%
experience an aggressive course.5,6 In 30% of the patients, the disease distribution is
left-sided. Symptoms of UC include diarrhea, rectal bleeding, urgency, tenesmus, and
fecal incontinence. Patients with UC are at risk of dysplasia and cancer. Between 10%
and 15% undergo colectomy to manage disease or its complications.7
Current medical treatment includes aminosalicylates, corticosteroids, thiopurines,
and calcineurin inhibitors. Anti-TNFα antibodies8–11 are available, but contraindica-
tions, primary non-response, loss of response, and intolerance often occur.
In addition to TNFα, there are several other cytokine pathways involved in the
development of UC.12 The IL-23/IL-17 axis is important in human IBD, with
elevated Th17 cytokines in human IBD.13 TGFβ-deﬁcient mice develop severe multi-
organ lymphoproliferative disease.14 IL-10-deﬁcient mice develop spontaneous
colitis.15 The discovery of speciﬁc pathways involved in IBD has led to more speciﬁc
medications targeting these, e.g., ustekinumab targeting the p40 subunit shared
between IL12 and IL23. UC is, however, most likely a heterogeneous condition,
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with multiple different immune pathways involved in an
individual resulting in a common phenotype – therefore,
suppression of more than one cytokine pathway may be
beneﬁcial.
Tofacitinib (XELJANZ/XELJANZ XR; Pﬁzer, NY, USA)
is an oral small molecule pan-Janus kinase (JAK) inhibitor
(molecular weight 312.4 Da; 504.5 for the citrate salt). This is
the ﬁrst oral formulation for the treatment of UC; tofacitinib
is less immunogenic than the larger biologic antibodies, has
a shorter half life, and has therefore got the advantage of
allowing rapid discontinuation in cases of adverse events.16
The JAKs are the downstream signaling molecules of
a large number of the cytokine pathways involved in IBD.17
When a cytokine binds its cell surface receptors, it
dimerizes the ligand receptors and this results in phosphor-
ylation of the JAK molecules. JAK then activates signal
transducer and activator of transcription molecules (STATs),
the phosphorylation of which results in STAT migration to
the nucleus and activation of gene transcription.17 By tar-
geting JAK signaling, it is possible to affect multiple cyto-
kine pathways thought to be involved in colitis.
Tofacitinib had been initially approved for the treatment
of moderate-to-severe rheumatoid arthritis (RA) [2012] and
psoriatic arthritis (PsA) [2017] in adult patients with inade-
quate response or intolerance to prior disease-modifying
antirheumatic drug therapies.18 Phase II and phase III trials
showed promising results in UC, leading the Food and Drug
Administration (FDA) and the European Medicines Agency
(EMA) to approve tofacitinib for the induction and main-
tenance of remission in moderate-to-severe UC.19,20 For
induction, 10 mg is given orally twice daily for 8-week
period, followed by a maintenance dose of 5 mg twice
daily.19,20 Nevertheless, in case of inadequate response by
week 8, the dose of 10 mg can be extended for another 8
weeks (16 weeks total) prior to attempting dose reduction or
can be maintained at 10 mg in those patients who had
previously failed anti-TNFα.19 We review the pharmacoki-
netic properties, efﬁcacy, and safety of tofacitinib in UC.
Search Strategy
Medline, PubMed, and Scopus search were undertaken by
two of the authors (G.M and K.A). The search criteria used
were “JAK inhibitor”, “tofacitinib”, “CP-690 550”,
“Ulcerative colitis”, “pharmacokinetic”, “side effects”,
“adverse events”, and “complications”. A manual search of
the clinical trial register, article reference lists, abstracts from
Digestive Disease Week, United European Gastroenterology
Week, and European Crohn’s Colitis Organization
congresses were also conducted up to the 17th of
May 2019. After an initial title screen, each relevant article
was subsequently reviewed.
Overview of JAKs
JAKs compose a family of tyrosine kinases, that includes
four large peptide members (≥1100 amino acids/molecular
mass: 120–140 kilodaltons), named JAK 1, JAK 2, JAK 3,
and Tyrosine Kinase 2 (TYK-2). Of the four family mem-
bers, JAK1, JAK2, and TyK2 are ubiquitously expressed,
whereas JAK3 is preferentially expressed in hematopoietic
cells.17,21 All family members have an evolutionary con-
served structure, which encompasses the catalytically active
and inactive functions of the enzymes and are associated with
the different chains of type I/II cytokine receptors
intracellularly21,22 A large group of cytokines, including
those involved in the pathogenesis of UC, employ type
I and II transmembrane receptors that rely on JAKs for
intracellular signaling.17 JAK1 and JAK3 are downstream
of cytokine receptors containing the IL-2 receptor common γ
chain (e.g., IL-2, IL-4, IL-7, IL-9, IL-15, IL-21), while JAK2
transduce signals from the cytokines binding to hematopoie-
tic growth factor and gp40-containing cytokine receptors. At
least two homologous (e.g., JAK2/JAK2) or heterologous
(e.g., JAK1/JAK3) JAK molecules are required from each
receptor in order to signal. Cytokine binding to the receptor
leads to JAK activation, auto-phosphorylation, and phos-
phorylation. This interaction forms speciﬁc binding sites,
recruits one or more members of a family of transcription
factors, termed STAT (Signal Transducer and Activator of
Transcription) proteins, and induces their subsequent
phosphorylation.17 Once activated, STATs dissociate from
the receptor and form homo-or hetero-dimers and translocate
to the nucleus, where they bind to DNA sequences, and
inﬂuence gene expression17,21 as demonstrated in Figure 1.
JAKs regulate a variety of cytokine-mediated processes
including hematopoiesis, inﬂammation, innate, and adaptive
immunity. Aberrant activation of JAKs peptides has been
shown to lead either directly or indirectly to a variety of
autoimmune and inﬂammatory disorders, including UC.23
Hence, it is of no surprise that the pharmacological inhibi-
tion of JAK has gained signiﬁcant attention as a therapeutic
target in immune-mediated disorders, with recent genome-
wide association studies supporting the rationale of target-
ing JAKs in UC.23,24 The JAK cytokines, however, are not
responsible for all cytokine signaling. For example, TNFα
mediates gene expression through the NF-kB, JUN kinase,
p38 MAPK, and ERK1/ERK2 pathways.25
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JAK Inhibition and Tofacitinib:
Mechanism of Action
Tofacitinib (CP-690, 550) was one of the ﬁrst JAK inhibi-
tors investigated. After demonstrating signiﬁcant immuno-
suppressive effects in pre-clinical animal models of
transplantation26,27 and arthritis,28 tofacitinib entered
clinical trials in patients with RA. Tofacitinib has undergone
further assessment in various other immune-mediated con-
ditions, including PsA and UC.29
In order to exert its pharmacologic action, tofacitinib
diffuses intracellularly, and then binds to the adenosine
triphosphate (ATP) binding site in the catalytic cleft of
the kinase domain of JAKs. This action inhibits JAK’s
subsequent phosphorylation and STAT activation,30 and
attenuates downstream cytokine production with
a consequent downregulation of the immune response.31
Tofacitinib is a pan-JAK inhibitor.28 Although in vitro
studies suggested that tofacitinib inhibits JAK1, JAK2,
JAK3, and to a lesser extent TYK2 in human cells,
in vivo studies have demonstrated it preferentially inhibits
JAK1 and JAK3 pathways.28 As a result, tofacitinib was
shown to disrupt to greater extent signaling from JAK3-
and JAK1-dependent cytokines (e.g., IL-2, IL-6, interfer-
ons [IFN], IL-12, IL-4, IL-7, IL-15, and IL-21), affecting
lymphocyte activation, proliferation, and function that are
crucial for multiple aspects of the immuno-inﬂammatory
response observed in UC.27,28,32
Pharmacokinetic Proﬁle
The pharmacokinetic (PK) proﬁle of tofacitinib has been
studied in healthy volunteers and in patients with RA,
PsA, and UC.
In healthy volunteers, tofacitinib’s time to serum peak
concentrations is between 0.5 and 1 hrs, and it is elimi-
nated in 3 hrs. No correlation was observed between
dosage and lymphocyte subsets in healthy volunteers.33
In UC, plasma tofacitinib concentrations increased propor-
tionally with dose and steady-state levels did not change
between baseline and 8 weeks. Steady-state concentrations
did not differ according to disease activity34 neither in UC
nor in psoriatic arthropathy.35
The majority (70%) of the drug is cleared by the liver,
with 30% being renally excreted.16 The clearance of tofa-
citinib is mediated by cytochrome P450 (CYP) 3A4; how-
ever, it does not affect the clearance of other drugs
metabolized by CYP enzymes.36 Use of other drugs that
inhibit CYP 34A systems such as ﬂuconazole and ketoco-
nazole increased the half-life of tofacitinib by an hour.
This would suggest that some dosage adjustment is
required in the context of concomitant CYP34A inhibitor
usage.37 CrCl also affects the half-life of tofacitinib.35
Population PK analysis from 1096 UC patients with
moderate-to-severe disease activity, pooled across one
phase 2 and three phase 3 studies, revealed comparable
Figure 1 Overviewof themechanism of action of Janus kinases (JAKs).Cytokine binding
to type I/II receptor at the cytoplasmic side of the plasma membrane leads to JAK
activation and phosphorylation. (Α) This subsequently initiates recruitment of two signal
transducer and activator of transcription proteins (STATs) and induces their subsequent
phosphorylation (Β). Once phosphorylated, STAT homodimerize or heterodimerize (C)
and translocate to the nucleus where they regulate gene transcription (D).
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PK properties for tofacitinib with those observed in other
immune-mediated conditions such as PsA and RA. Based
on this comparability, all proposed dosing adjustment
recommendations derived from phase 1 studies in RA
are also applicable to UC patients. Consequently, in UC
patients with moderate renal (deﬁned as creatinine clear-
ance values less than 60 mL/min), it is suggested to
reduce to dose of tofacitinib by half. In contrast, no
dose modiﬁcation has been shown to be required for
tofacitinib in association with a variety of other patient-
and disease-related factors including age, body weight,
sex, ethnicity, and baseline disease severity (e.g., baseline
Mayo score and baseline albumin). Tofacitinib has not
been studied in the context of severe hepatic
impairment.19
Therapeutic Efﬁcacy of Tofacitinib in
UC
A summary of the market-authorizing trials of tofacitinib’s
in UC included in this review is shown in Table 1.
Phase II Studies
Sandborn et al investigated tofacitinib in a multi-center,
double-blinded, randomized controlled trial over an
8-week period for moderate-to-severe UC.38 Patients
were assigned to placebo administered twice daily or tofa-
citinib (at doses of 0.5, 3 10, or 15 mg twice daily). The
primary endpoint was clinical response (a decrease from
baseline total Mayo score by at least 3 points and a relative
decrease by at least 30%) at the end of the 8-week period.
The secondary endpoint was clinical remission deﬁned as
a total Mayo score of 0 to 2.
At 8 weeks, clinical response was observed in 32%,
48%, 61%, and 78% of the patients receiving tofacitinib at
doses 0.5, 3, 10, and 15 mg BD, respectively (p values
0.39, 0.55, 0.10, and <0.001), compared with 42% of the
patients receiving placebo. Endoscopic response was
observed in 52%, 58%, 67%, and 78% of the patients on
tofacitinib at doses of 0.5, 3, 10 and 15 mg BD, respec-
tively, compared to 46% of the placebo (p values 0.64,
0.30, 0.07, and 0.001).
Although its highest efﬁcacy was shown to be expected
from doses ≥ 10 mg twice daily, safety concerns (dose-
dependent hyperlipidemia and viral infections) that have
arisen from patients with RA receiving more than 15 mg
BD39 has led the FDA to select the 10 mg dose for the
subsequent clinical development of tofacitinib in UC.38
Efﬁcacy in Phase III Trials
Induction of Remission and Mucosal Healing
The efﬁcacy of tofacitinib in the induction of remission in
patients with moderately-to-severely active UC was inves-
tigated in two multi-center, double-blind, placebo-
controlled phase 3 trials, named OCTAVE (Oral Clinical
Trials for tofAcitinib in ulceratiVE colitis) Induction 1 and
2.40 In these trials, 1139 eligible patients were randomized
(4:1) to receive tofacitinib 10 mg or placebo twice a day
for an 8-week period. The patients had moderately-to-
severe active (mean total Mayo score: 9) extensive colitis
(52%) with a median disease duration of 6 years, mean age
of 41years, with 59% of the participants being male and
80% caucasian. Approximately 70% of the patients had
previously failed immunosuppressants other than biologic
agents or corticosteroids, 52% had failed treatment with
anti-TNFα (56% primary non-responders), and 46% were
taking oral corticosteroids upon entry. Aminosalicylates or
prednisolone up to 25 mg OD was allowed over the treat-
ment period, but no immunomodulators or biologic thera-
pies. The primary endpoint was clinical remission at 8
weeks (deﬁned as a total Mayo score ≤2 points, no indi-
vidual subscore >1, rectal bleeding subscore of 0). The key
secondary endpoint was mucosal healing (MH deﬁned as
endoscopic subscore of 0 or 1) at 8 weeks. Clinical remis-
sion at 8 weeks occurred in 19% and 17% of the tofaciti-
nib group, whereas the placebo groups had a remission
rate of 8% and 4% in OCTAVE Induction 1 and 2, respec-
tively (both comparisons were statistically signiﬁcant).
MH was achieved in 31% (OCTAVE 1) and 28%
(OCTAVE 2) in tofacitinib versus 16% and 12% in those
receiving placebo (p<0.001).
In both induction trials, subgroup analysis showed no
signiﬁcant differences in the efﬁcacy of TOF over placebo
for ethnic origin, previous experience to anti-TNFα and
concomitant use of aminosalicylates.40,41 At all visits,
patients receiving TOF had larger improvement in partial
Mayo score compared to placebo with signiﬁcant reduc-
tions in stool frequency.42
Maintenance of Remission and Mucosal Healing
A total of 593 patients from the OCTAVE Induction 1 or 2
trial who achieved clinical response at the end of 8 weeks
with TOF 10 mg twice daily were re-randomized, in a 1:1:1
ratio into OCTAVE Sustain. These patients received main-
tenance therapy with tofacitinib 5 or 10 mg twice daily or
placebo for 52 weeks. In this trial, 30% of the participants
were in remission upon entry. The primary endpoint of
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OCTAVE Sustain was remission at 52 weeks. Key secondary
endpoints were the achievement of MH at 52 weeks and of
sustained glucocorticoid-free remission deﬁned as glucocor-
ticoid-free remission at 24 and 52 weeks. At 52 weeks, 34%
of the 5 mg tofacitinib group, 41% in the tofacitinib 10 mg
group, and 11% in the placebo group were in remission. As
high as 37% in the patients receiving tofacitinib 5mg, 46% of
the tofacitinib receiving 10 mg, and in 13% of those receiv-
ing placebo had achieved MH. With regard to the other key
efﬁcacy endpoints, sustained and glucocorticoid-free remis-
sion were achieved by 35% and 47% of the 5-mg and 10-mg
tofacitinib treatment arms as compared with the placebo arm,
respectively (5%, p <0.001 for both comparisons).40
In subsequent subgroup analysis, no signiﬁcant differ-
ences in efﬁcacy of tofacitinib over placebo with regard to
patients’ race and concomitant use of aminosalicylates40,41,43
were noted. In addition, irrespective of the tofacitinib dose
received or anti-TNFα failure status, patients who entered the
trial in remission were more likely to remain in remission or
MH at week 52, compared to those who had not achieved
remission after induction.44 At all visits, patients receiving
tofacitinib had better improvements in the partial Mayo score
as compared to those receiving placebo (p < 0.001 for all
comparisons).40,41
Long-Term Efﬁcacy
The long-term efﬁcacy of tofacitinib is being evaluated in an
ongoing, open-label, long-term extension (OLE) study,
named OCTAVE Open. In OCTAVE Open, all patients
who had completed or experienced treatment failure in
OCTAVE Sustain as well as non-responders to tofacitinib
from OCTAVE Induction 1 and 2 were included (Figure 2).
The preliminary results of this study are summarized below.
Recapturing Response
Loss of Response Secondary to Treatment Interruption
The effect of tofacitinib in recapturing response after treat-
ment interruption was studied in a subpopulation of 101
patients entered into the OCTAVE Open trial. These patients
had achieved clinical response with tofacitinib 10 mg twice
daily in the OCTAVE Induction trials, but experienced treat-
ment failure – loss of response – in the maintenance study
after being randomized to receive placebo. Treatment failure
was deﬁned as increase ≥3 points from OCTAVE Sustain
baseline total Mayo score plus increase in rectal bleeding
subscore and endoscopic subscore ≥1 point and absolute
endoscopic subscore ≥2 points after ≥8 weeks of mainte-
nance therapy. All of these patients received tofacitinib
10mg twice daily in the OLE study. Study outcomes
included clinical response, MH, and remission at months 2
and 12 of OCTAVE Open. At month 2, 76%, 55%, and 40%
of the subpopulation achieved clinical response, MH and
clinical remission, respectively. Similar ﬁndings were iden-
tiﬁed at 12 months in these key outcomes. Based on their
ﬁndings, Panes et al suggested that in tofacitinib responders
who lost response secondary to treatment interruption
Figure 2 Flowchart of participants progress through the OCTAVE trials.
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retreatment with 10 mg twice daily, recaptures response in
approximately three-quarters of patients within 2 months
and sustains the response up to 1 year.45
Loss of Response Secondary to Dose Reduction
Tofacitinib to recapture response after dose reduction was
investigated in a subpopulation of 58 patients who had
initially responded to tofacitinib in the OCTAVE Induction
trials but lost response in the maintenance study after being
allocated to tofacitinib 5 mg twice daily. All of these
patients were treated with tofacitinib10 mg twice daily in
the OLE study. Study outcomes included clinical response,
MH, and remission at months 2 and 12. At month 2, 58.6%,
41.4%, and 34.5% of the patients achieved clinical
response, MH, and clinical remission, respectively. Similar
ﬁndings were identiﬁed at 12 months in these key outcomes
(68.8%, 60.4%, and 52% for clinical response, MH, and
remission, respectively). Based on these data, Sands et al
suggested that in tofacitinib responders who lost response
secondary to dose reduction for maintenance, retreatment
with 10 mg twice daily recaptures response for most
patients within 2 months following dose escalation.46
Induction of Response in Non-Responders to the Initial
8-Week Course (Delayed Response)
The efﬁcacy of tofacitinib in inducing response in patients
who failed to respond to an initial 8-week of tofacitinib
10 mg twice daily was investigated in 295 patients from
both OCTAVE Induction trials. All of these patients con-
tinued to receive tofacitinib 10 mg twice daily in the OLE
study. Study outcomes included clinical response, MH,
and clinical remission evaluated at months 2, 12, 24, and
36. At month 2, clinical response was observed in 51% of
the subpopulation, with 72%, 61%, and 54% of the
patients preserving response at 12, 24, and 36 months,
respectively. Approximately half of the patients were in
remission (49%, 45% and 45% at months 2, 12, 24, and
36, respectively), while MH was observed in the majority
of patients (57%, 53%, and 51% at months 2, 12, 24, and
36, respectively) at any time-point after the ﬁrst year of
treatment. Similar trends over time were observed when
prior failure to anti-TNFα was taken into consideration.
Based on these ﬁndings, Rubin et al suggested that
a substantial proportion of non-responders to the initial
8-week course of tofacitinib at dose 10 mg twice daily
respond to an extended induction course and achieved
response lasting up to 3 years, irrespective of patients’
previous failure status to anti-TNFα.47
Improvement of Remission After 52 Weeks of Response
The efﬁcacy of tofacitinib in achieving remission after
prolonged response was investigated in a subpopulation
of 82 patients who had responded to tofacitinib at 52
weeks. Of the 82 patients, 1 entered the Sustain trial in
error, 18 were randomized to receive placebo, 28 to tofa-
citinib 5 mg twice daily and 35 to tofacitinib 10 mg twice
daily. All of these patients received tofacitinib 10 mg twice
daily in the OCTAVE Open trial. Efﬁcacy endpoints
included clinical response, MH, and clinical remission at
months 2, 12, 24, and 36. At 24 months, clinical response
was maintained by 70% of the patients. No difference in
clinical response was observed between participants who
had previously failed (65%) or not failed (73%) anti-TNFα
therapy. By month 2, remission rates were improved in the
majority of patients regardless of anti-TNFα failure status
(59% [48/82], 61% [23/38] and 57% [25/44] of the total
number of patients and of those with and without failure to
anti-TNFα, respectively). Similar trends were observed
with regard to MH over time. Based on these data, tofaci-
tinib 10 mg twice daily was shown to be effective in
inducing remission in UC patients with prolonged
response who had not achieved remission, regardless of
their previous failure status to anti-TNFα.48
Maintenance of Remission Following Dose Reduction
The maintenance of remission for patients following a dose
reduction in tofacitinib was investigated in a cohort of 76
patients from the SUSTAIN trial.49 All of these patients
were in remission at 52 weeks on tofacitinib 10 mg twice
daily and subsequently received tofacitinib 5 mg twice daily
in the OPEN study. Based on the time-point in the
SUSTAIN trial that remission state was achieved, the
patients were further divided into 3 groups. Patients who
were in remission at baseline in the SUSTAIN trial were
included in the ﬁrst group (remission ≥12 months pre-dose
reduction); patients in remission at 24 weeks were included
in the second group (remission 6–<12 months pre-dose
reduction); and patients in remission at 52 weeks were
included in the third group (remission <6 months pre-dose
reduction). Overall, rates for maintenance of remission were
82% at 12 months and 76% at 24 months in the OPEN study.
Among the 3 different groups, the remission rates at 12
months were 91% for the ﬁrst group, 82% for the second
group, and 71% for the third group. This data suggest that
the majority of UC patients who achieved stable remission
with tofacitinib 10 mg twice daily and dose reduced to 5 mg
twice daily maintained remission for up to 24 months
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following the dose reduction, although the authors high-
lighted that this beneﬁt may be greater in those patients
who are in remission for ≥6 months prior to dose reduction.
Effect on Health-Related Quality of Life (HRQoL)
The effect of tofacitinib on HRQoL was investigated
across the single phase II, the two OCTAVE Induction
and the single OCTAVE Sustain trials. This was performed
using the disease-speciﬁc Inﬂammatory Bowel Disease
Questionnaire (IBDQ) in the phase II trial, and both the
IBDQ and generic SF-36v2® Health Survey (SF-36) in the
other trials.
In the phase II trial, IBDQ was completed at baseline
(day 1), with total scores being similar across all treatment
groups, ranging from123.2 to 134.5.52 Atweek 8,mean IBDQ
total scores had dose-proportionally improved compared to
baseline measurements across all ﬁve treatment groups (week
8 range 149.6–175.4), with the improvement being signiﬁ-
cantly higher over placebo (p = 0.001) only for those patients
who received tofacitinib 15 mg twice daily. Patients in endo-
scopic remission were found to have signiﬁcantly higher
IBDQ scores than those who had not achieved endoscopic
remission.
In the two induction trials, IBDQ was completed at
baseline (day 1), week 4, and week 8, whereas SF-36 was
completed at baseline and week 8.53 At week 8, mean
changes from baseline IBDQ were higher in those patients
treated with tofacitinib 10 mg twice daily (40.7 and 44.6)
compared to those receiving placebo (21.0 and 25.0,
p <0.0001). Similar ﬁndings were observed for SF-36,
which measures mean changes from baseline in Physical
and Mental Component Summaries (PCS/MCS). The
OCTAVE induction 1 and 2 trials show PCM 6.8 and
6.8, and MCS 6.8 and 7.6, respectively, for those patients
receiving tofacitinib 10 mg vs PCS 2.5 and 4.6 and MCS
3.5 and 4.4 for those receiving placebo (p < 0.01). In both
trials, HRQoL was found to be signiﬁcantly correlated
with clinical remission and mucosal healing. In the
Sustain trial, IBDQ was completed at weeks 8, 16, 24,
32, 40, and 52, whereas SF-36 was completed at weeks 24
and 52. At week 52, changes from baseline in IBDQ total
scores were maintained with tofacitinib (3.7 for those
receiving 5 mg twice daily and 4.8 for those at 10 mg)
as compared to placebo (−26.5, p < 0.0001). The conclu-
sion for the observed changes in the PCS (0, 0.3 for
tofacitinib 5 and 10 mg twice daily vs −5.2 for placebo,
p<0.0001) and MCS subscores (−1, 0.1 for tofacitinib 5
and 10 mg vs −6.7 for placebo, p<0.0001) of SF-36 was
similar.
Overall, tofacitinib was found to result in signiﬁcant
improvements in HRQoL compared to placebo, and this was
strongly related to clinical and endoscopic remission. Similar
conclusions were reached when data from the induction and
maintenance trials were re-analyzed, using the comparatively
more stringent IBDQ criteria for remission (total score ≥190)
and response (≥30-point increase from baseline).50
Real-World Experience
The real-world experience of tofacitinib in the manage-
ment of active UC derives from three retrospective studies
from tertiary referral centers across USA and France
(Table 2). Weisshof et al describe their experience of
tofacitinib in a cohort of 58 patients with inﬂammatory
bowel disease with UC, 4 with Crohn’s disease, 1 with
Table 2 Real-World Studies
Number Previous Biologics Dose Outcomes
Weisshof et al (51) 58 patients
(53 with UC)
93% failed TNFi
81% failed VDZ
60% (n=30) received 10 mg BID
38% (n=22) received 5 mg BID
2% (n=1) received 11mg ER OD
Week 8 clinical response 69%, clinical
remission 33%, and corticosteroid-free
remission 26%
Week 52 corticosteroid-free remission 27%
Ungaro et al (52) 123 patients
with UC
28.5% biologic naïve
40.7% failed both
TNFi & VDZ
All received 10mg BID Week 8 clinical response 60.8% and
clinical remission 13.5%
Week 16 response 55.4%, remission
48.6% (n=74)
Month 6 endoscopic healing 64.9% (n=57)
Lair-Mehiri et al
(53)
37 patients
with UC
All failed TNFi
97% failed VDZ
All received 10 mg BID Week 24 colectomy-free survival 77%,
clinical response 41%, and corticosteroid-
free remission 32%
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pouchitis).51 The majority (93%) of the patients had pre-
viously failed treatment with anti-TNFα and 81% had
failed treatment with vedolizumab, thus constituting
a highly medically refractory population. Tofacitinib dose
was selected based on symptom severity, with 35/58
(60%) receiving tofacitinib 10 mg twice daily, 22/58
(38%) receiving tofacitinib 5 mg twice daily, and one
patient receiving an extended-release tofacitinib 10 mg
once daily. Of those receiving 10 mg twice daily, 7
patients started on tofacitinib 15 mg twice daily for severe
disease before reducing to 10 mg twice daily within 2–4
weeks due to limited efﬁcacy. Of those receiving 5 mg
twice daily, 10 patients were escalated to 10 mg twice
daily, with 8 achieving clinical response. All patients
received tofacitinib for at least 8 weeks and clinical
response (deﬁned as symptomatic improvement from base-
line) was assessed at 8, 26, and 52 weeks. After 8 weeks of
treatment, 21 patients (36%) achieved a clinical response
and 19 (33%) achieved clinical remission, corresponding
to an overall response rate of 69%. The proportion of
patients still being maintained on tofacitinib at 3, 6, and
12 months was 69%, 55%, and 51%, respectively.
Corticosteroid-free remission occurred in 26%, 21%, and
27% of the patients at 8, 26, and 52 weeks, respectively.
In another cohort study from six centers in the USA,
Ungaro et al retrospectively reviewed the data of 123
patients with active UC who received tofacitinib 10 mg
twice daily for at least 8 weeks.52 A minority (28.5%) of
patients were biologic naïve, whilst 40.7% had been
exposed to both anti-TNFα and VDZ. Clinical response
(deﬁned as >50% reduction in symptoms) and clinical
remission (deﬁned as absence of symptoms) was assessed
at week 8 and week 16, and endoscopic healing (deﬁned as
Mayo endoscopic score ≤1 or absence of erosions/ulcera-
tions) was assessed within 6 months of initiating tofaciti-
nib. Ninety-six patients completed 8 weeks of treatment
with an overall clinical response of 60.8% and clinical
remission of 13.5%. At week 16, 74 patients remained
on tofacitinib, with a clinical response of 55.4% and clin-
ical remission of 48.6%. The majority of patients (64.9%,
n = 57) achieved endoscopic healing at 6 months.
Subgroup analysis showed that those patients naive to
biologics responded signiﬁcantly better to tofacitinib than
those with previous exposure. The patient’s naïve status
(adjusted odds ratio [aOR] 5.50, 95% CI 1.71–17.65), the
concomitant use of corticosteroids (aOR 0.25, 95% CI
0.07–0.83) and male gender (adjusted hazard ratio 0.25,
95% CI 0.08–0.83) were found to be independently asso-
ciated with clinical response at week 8.
A French multi-center retrospective study included 37
patients with medically refractory UC treated with tofaci-
tinib 10 mg twice daily for at least 24 weeks.53 All patients
had previously been treated with a TNFi and 97% with
VDZ. The primary endpoint was colectomy-free survival
rate at week 24 and was achieved in 77% of the patients.
Survival without drug interruption was seen in 25 patients
(62.6%, 44.3–76.4%) at week 24 and 9 patients at week 48
(58.2%, 39.2–73.1%). At 24 weeks, clinical response was
achieved by 41% of the patients, with 32% being in
a corticosteroid-free clinical remission status.
Collectively, these three studies show that tofacitinib is
an effective treatment in the management of refractory UC
in a real-world setting.
Comparative Efﬁcacy of Tofacitinib vs
Biological Therapies
In the absence of head-to-head trials, evidence of the
comparative efﬁcacy of tofacitinib and biological therapies
is based on indirect evidence from four network meta-
analyses (NMA). These all compared tofacitinib with
antiTNFα (inﬂiximab, adalimumab, golimumab) and anti-
integrins (VDZ), and all synthesized data from randomized
controlled phase II and/or III trials. Three out of four
NMAs used clinical (response and remission) and endo-
scopic (MH) efﬁcacy endpoints as outcomes,54–56 whereas
one used HRQoL.57
Singh and Bonovas undertook their analyses of clinical
and endoscopic endpoints in anti-TNFα naïve cohorts by
basing their probabilities of each treatment being superior.
The authors concluded that inﬂiximab and VDZ may be
superior for the induction of clinical response, remission,
and MH.58,59 Trigo-Vicente et al reached similar
conclusions.56 However, the addition of ozanimod (a
sphingosine-1-phosphate receptor agonist) and etrolizu-
mab (an anti-adhesion molecule antibody) in their analysis
showed that ozanimod may be better than inﬂiximab for
the achievement of MH. In contrast, for patients who were
anti-TNFα experienced, tofacitinib was ranked higher for
the induction of remission and of MH compared to the
other available treatments.58 For the maintenance of remis-
sion, no indirect comparisons were performed for anti-
TNFα experienced patients.54–56 However, in anti-TNFα
naïve patients, Trigo-Valente et al found that tofacitinib
had the highest probability of being the best treatment in
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the maintenance of remission, sustained remission and
for MH.
With regard to the impact of different therapies on
HRQoL, at induction, Paschos et al found that all of the
compared therapies signiﬁcantly improved both generic
and disease-speciﬁc HRQL scores compared to
placebo.57 However, the improvement was clinically
meaningful only for inﬂiximab (18.58; 95% CI 13.19–
23.97) and VDZ (18.00; 95% CI 11.08–24.92). For main-
tenance, VDZ, tofacitinib, and adalimumab were found to
maintain the improvement in HRQL.
Safety of Tofacitinib in UC
The ﬁrst centralized evaluation of the short- and long-term
safety proﬁle of tofacitinib in the management UC was
recently published.58 The report was focused on speciﬁc
adverse events (AEs), including herpes zoster (HZ), oppor-
tunistic infections (OIs), malignancies, non-melanoma
skin cancers (NMSC), major adverse cardiovascular
events (MACE), and gastrointestinal perforations. The
safety data were collated from the four aforementioned
market-authorizing trials, including 1157 patients over
a 4.4-year period (1612.8 patient-years of exposure).
They were analyzed as 3 cohorts: the induction cohort,
which included data from patients randomized to placebo
or tofacitinib from the dose-ﬁnding phase II and the two
phase III induction trials; the maintenance cohort, that
included data from patients from the Sustain trial; and
the laboratory cohort that included data from patients
from the induction and the sustain cohort who were eval-
uated for changes over time in laboratory parameters.
Serious adverse events (SAEs) were deﬁned as any events
threatening life, resulting in death, causing persistent or
signiﬁcant disability or incapacity, requiring or prolonging
hospitalization, or causing congenital anomaly or birth
defect.
In the induction cohort, 54.9% of the patients devel-
oped AEs and 3.8% developed SAEs resulting in tofaciti-
nib being stopped. Similar rates were seen in patients
receiving placebo, with AEs in 55.0% and SAEs in
5.0%. In contrast, higher rates of AEs (75.3%, 72.2%,
and 79.6% for those receiving placebo, tofacitinib 5 mg,
and 10 mg twice daily, respectively) and of SAEs (6.6%,
5.1%, and 5.6%) were found across all of the treatment
arms in the maintenance cohort.
The most frequent adverse events seen in the induction
cohort were headache (6.7% for placebo, 7.8% for tofaci-
tinib 10 mg) and nasopharyngitis (5.0% for placebo, 6.0%
for tofacitinib 10 mg), whereas nasopharyngitis (5.6% for
placebo, 9.6% for tofacitinib 5 mg, 13.8% for tofacitinib
10 mg) and worsening of UC (35.9% for placebo, 18.2%
for tofacitinib 5 mg, 14.8% for tofacitinib 10 mg) pre-
vailed in the maintenance cohort. Serious infections (SI),
deﬁned as any treated infections that required parenteral
antimicrobial therapy, hospitalization, or fulﬁlled criteria
for SAEs, were rarely observed (IR: 2.0; 95% CI: 1.4–2.8).
However, there were four types of SI that were reported
more than once including appendicitis, herpes zoster infec-
tion (HZ), anal abscess, and Clostridium difﬁcile infection.
None of these infections were fatal.
In the maintenance cohort, the incidence ratio for HZ
was found to be increased in UC, with greater values being
observed in those patients receiving tofacitinib 10 mg com-
pared to those receiving tofacitinib 5 mg or placebo. This
ﬁnding signiﬁed a dose-proportional increase of the asso-
ciated risk for HZ. In the overall cohort, there were
recorded 18 cases of HZ, with older age, prior anti-TNFα
failure, and non-white (mainly Asians) race being indepen-
dently associated with an increased risk for developing HZ.
However, in most cases, HZ infection was cutaneous over 1
or 2 adjacent dermatomes and did not require permanent
discontinuation of tofacitinib. A more detailed analysis of
HZ events in the UC program has been reported by
Winthrop et al.59 In this study, based on their previous
experience in RA, the authors suggested that vaccination
against HZ could be a possible preventive strategy for non-
exposed UC patients; however, in the absence of robust data
from UC, vaccination is not currently recommended. An
ongoing randomized controlled trial evaluating the safety
and immunogenicity of HZ vaccine across a variety of
immune-mediated disorders, including patients with UC
(VERVE trial, NCT02538341),60 is expected to provide
some more deﬁnitive results on this.
During the observation period in the OCTAVE trials,
four deaths were recorded in the overall population, with 3
out of 4 cases being secondary to malignancies (hepatic
angiosarcoma, acute myeloid leukemia, and cholangiocar-
cinoma). In the overall cohort, 22 patients were diagnosed
with malignancy, with 50% of the cases having NMSC.
The majority (18 out of the 22) of patients were experi-
enced with anti-TNFα and thiopurines, whereas 6 out of
the 11 with NMSC had previous history of NMSC.
Overall, malignancies were rarely observed.
With regard to other adverse events, 3 cases of colonic
perforations and 4 MACEs (hemorrhagic stroke, aortic
dissection, acute coronary syndrome, and myocardial
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infarction) were recorded in the study. Nearly all of the
involved (5/7) patients had multiple risk factors that may
have contributed to the development of these complica-
tions. In particular, 2 out of the 3 cases of perforation
occurred in patients with a background of active UC
inﬂammation or Epstein–Barr virus intestinal lymphoma
who were recently prescribed corticosteroids and under-
went an endoscopic procedure, whereas the third case
occurred in a patient who developed appendicitis and
received concomitant nonsteroidal anti-inﬂammatory
drugs. Likewise, 3 out of 4 with MACE had ≥4 predispos-
ing cardiovascular risk factors. However, other than a case
of aortic dissection that resulted in death, all of the other
MACE were resolved after temporary or permanent dis-
continuation of TOF.
No clinically meaningful changes were observed in
various laboratory parameters, including the low-density
lipoprotein/high-density lipoprotein ratio, hemoglobin,
absolute lymphocyte count, and creatine kinase.61
An update of the results of this study was presented by
Sandborn et al in the most recent ECCO 2019 conference,
extending our knowledge on the safety proﬁle of tofaciti-
nib by 1 year.62 No additional or unexpected safety signals
were identiﬁed, supporting the long-term use of tofacitinib
in patients with moderately to severely active UC.
Safety of Tofacitinib vs Biological
Therapies
As with comparisons of the efﬁcacy between tofacitinib
and biological therapy, comparative safety data are derived
indirectly from NMAs. Trigo-Vicente et al showed that all
comparative treatments were more likely to cause SAEs
than placebo and that all therapies had similar probabilities
of causing SAEs.60 With regards to opportunistic infec-
tions, tofacitinib had the highest rate (although most were
minor), whilst golimumab and vedolizumab also showed
increased rates, and inﬂiximab and adalimumab did not
show a statistically signiﬁcant increased rate compared to
placebo.
Safety of Tofacitinib in Speciﬁc
Populations
The safety of tofacitinib in children, pregnant women, and
elder patients has not been directly studied in UC. However,
Mahadevan et al recently reported pregnancy and infant
outcomes from patients with both maternal and paternal
prenatal exposure to tofacitinib who participated in the
ﬁve aforementioned UC clinical trials.63 Of the 1157
patients enrolled in these studies, 301 were women of child-
bearing age with 11 cases of maternal exposure and 14
cases of paternal exposure identiﬁed. In total, they reported
15 healthy newborns, no fetal or neonatal deaths, no con-
genital malformations, 2 spontaneous abortions, and 2 med-
ical terminations. These ﬁndings appear similar to those
reported from other clinical study populations and the gen-
eral population.64,65 Nevertheless, more data are clearly
needed to evaluate safety in this particular setting.67–69
Safety of Tofacitinib in Other Disease
Populations
The incidence ratio of adverse events of special interest in
the tofacitinib UC program was generally consistent with
those reported in the RA program. However, a post-
marketing study (A3921133) in RA found an increased
incidence of pulmonary embolism among patients over
50 years with more than 1 cardiovascular factor receiving
the 10 mg twice daily dose. This ﬁnding has led regulatory
authorities to restrict the use of tofacitinib in patients with
an increased risk for thromboembolism, which includes
heart failure, cancer, thrombophilia, previous history of
thromboembolic episodes, patients receiving hormonal
contraceptives or hormone replacement therapy and those
undergoing major surgery.66 An ongoing safety trial in RA
and future post-marketing studies in UC are expected to
shed more light into this relationship.
Potential Place in UC
Pharmacotherapy
Tofacitinib is the ﬁrst oral JAK inhibitor that has been
approved by the EMA and the FDA for the management of
adult patients with moderately to severely active UC. The
American College of Gastroenterology (ACG) has recently
positioned tofacitinib in the therapeutic algorithm of UC
either as ﬁrst-line therapy for moderate-to-severely active
disease or as second-line therapy in those who have failed
anti-TNFα.67 In addition, the real-world studies described
above show that tofacitinib can be used effectively as
third-line therapy in patients who have failed both anti-
TNFα and vedolizumab. Although the NMAs suggest
tofacitinib may be less effective than anti-TNFα as a ﬁrst-
line therapy and more effective as a second-line therapy,
more substantial evidence is needed to inform selection
preference.
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As tofacitinib is the latest therapy to be approved for
UC, its current use mostly assumes that of salvage therapy.
However, compared to the available biologics (inﬂiximab,
adalimumab, golimumab, and VDZ), tofacitinib has several
potentially favorable characteristics that could lead to its
preferential selection. Firstly, it is orally administered which
could improve therapy adherence and quality of life in
patients averse to the requirement for long-term injections
or infusions.68,69 Its pharmacokinetic proﬁle, characterized
by rapid absorption, metabolism, and clearance, is advanta-
geous in situations where rapid onset of action (e.g., acute
severe colitis) or elimination of the drug (e.g., infection,
surgery, or pregnancy) is required.70 Importantly, tofacitinib
is a small synthetic molecule that would not induce an
immunogenic response. Therefore, unlike the anti-TNFα
in particular, there is no risk of loss of response due to
antibody formation against the drug, negating the need for
combination therapy with an immunomodulator to prevent
this.35 In addition, tofacitinib would be expected to have
lower costs than the biologics, given it is a small molecule
with less elaborate production and will therefore have
a higher cost-effectiveness ratio.71–73
Future Directions
The evidence on the efﬁcacy and safety of tofacitinib for
the management of UC mainly arises from clinical trials
and pertain to restricted populations. Post-marketing stu-
dies are needed to expand clinicians’ experience on the
efﬁcacy and safety of tofacitinib in real-world populations,
including speciﬁc groups excluded from the licensing
trials (e.g., elders and children), and to address the poten-
tial thromboembolic risk highlighted in the RA population.
With the approval of tofacitinib for the management of
moderately-to-severely active UC, the available therapeu-
tic options have increased, creating an issue with selection.
Current evidence is insufﬁcient to support preferential
selection amongst the available therapeutic options and
direct head-to-head comparison trials are necessary to
address this issue.74
Conclusion
Tofacitinib is a valuable addition to the therapeutic arma-
mentarium for managing UC. The OCTAVE trials have
shown that tofacitinib is effective for the management of
moderately-to-severely active UC with a good overall
tolerance, although the potential risk of thromboembolism
seen in the RA population needs further evaluation.
Current recommendations issued by the ACG have
positioned tofacitinib alongside the established biologic
agents for both induction and maintenance of remission
of moderate-to-severely active UC. Although tofacitinib
possesses several favorable characteristics (e.g., oral
administration, lack of immunogenicity, rapid action, and
clearance), the exact place against more established biolo-
gical therapies will become more evident as clinical
experience with this novel agent improves.
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